PGNY
$18.06+0.64 (+3.67%)
Progyny, Inc., a benefits management company, provides fertility, family building, and women's health benefits solutions in the United States.
Historical Price
Peer Comparison
Whystock Valuation Model
Fundamentals
Progyny, Inc., a benefits management company, provides fertility, family building, and women's health benefits solutions in the United States. It offers fertility benefits solutions, such as differentiated benefits plan design that includes smart cyc...
Recent News
Assessing Progyny (PGNY) Valuation After Recent Share Price Weakness
Recent share performance and business snapshot Progyny (PGNY) has drawn attention after a period of weaker share performance, with returns of an 18.8% decline over the past month and a 34.5% decline over the past 3 months. This has prompted closer scrutiny of the underlying business. The company operates as a benefits manager focused on fertility, family building and women’s health in the United States. It generates US$1.29b in revenue and US$58.52m in net income from services that span...
3 Out-of-Favor Stocks with Open Questions
Hitting a new 52-week low can be a pivotal moment for any stock. These floors often mark either the beginning of a turnaround story or confirmation that a company faces serious headwinds.
Barclays Raises Hims & Hers (HIMS) Target to $29 After Novo Deal Clears Legal Overhang — Canaccord Cuts Progyny (PGNY) on Cautious 2026 Outlook
Two healthcare names are drawing fresh analyst attention this week as Wall Street recalibrates around a landmark GLP-1 truce and a fertility benefits company navigating a murky 2026 outlook. Barclays analyst Glen Santangelo raised his price target on Hims & Hers Health to $29 from $25, keeping an Overweight rating, after the company’s deal with ... Barclays Raises Hims & Hers (HIMS) Target to $29 After Novo Deal Clears Legal Overhang — Canaccord Cuts Progyny (PGNY) on Cautious 2026 Outlook
3 Cash-Producing Stocks We Think Twice About
Generating cash is essential for any business, but not all cash-rich companies are great investments. Some produce plenty of cash but fail to allocate it effectively, leading to missed opportunities.
Is Progyny (PGNY) Using Buybacks and Employee Stock Plans to Recast Its Growth Story?
In late February 2026, Progyny completed a share repurchase of 6,530,363 shares for US$159.4 million and filed a US$93.26 million employee stock offering shelf, alongside reporting higher 2025 sales and earnings versus the prior year and issuing 2026 revenue guidance that implies modest growth. The combination of a sizable completed buyback, new employee stock plan capacity, and revenue guidance that assumes the loss of a large transition client gives investors fresh information on how...